Last reviewed · How we verify
ACESULFAME
ACESULFAME is a marketed artificial sweetener that binds to sweet receptors on the tongue, mimicking the taste of sugar without providing its calories. Its key strength lies in its ability to provide a sugar-like taste without caloric content, positioning it as a popular choice in the low-calorie sweetener market. The primary risk is the expiration of its key composition patent in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | ACESULFAME |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Saccharin and Acesulfame Potassium Consumption and Glucose Homeostasis in Older Adults With Prediabetes (NA)
- SweetSpot - The Effect of Non-nutritive Sweeteners on Health (NA)
- Effect of Non-nutritive Sweeteners of High Sugar Sweetened Beverages on Metabolic Health and Gut Microbiome (NA)
- Intergenerational Transmission of Low-calorie Sweeteners Via Breast Milk (NA)
- The Effects of a Novel Mitochondrial Substrate Supplement on Exercise Performance and Cognitive Function (NA)
- Treatment of Radiation and Cisplatin Induced Toxicities with Tempol (PHASE2)
- Effects of Oral Xylitol on Subsequent Energy Intake (NA)
- Fluid Loading Countermeasures (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACESULFAME CI brief — competitive landscape report
- ACESULFAME updates RSS · CI watch RSS